Evidence map›Paper›PMID 21959366›Full record

ArticleOphthalmology2011

Ocular manifestations of trichothiodystrophy.

Brian P Brooks, Amy H Thompson, Janine A Clayton, Chi-Chao Chan, Deborah Tamura, Wadih M Zein, Delphine Blain, Casey Hadsall, John Rowan, Kristen E Bowles and 6 more

Abstract read
In one paragraph

Article in Ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Chemiexcitation: Mammalian Photochemistry in the DarkPhotochemistry and photobiology · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Chemiexcitation and Its Implications for Disease.Trends in molecular medicine · 2018
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Brian P BrooksNational Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. brooksb@mail.nih.gov
Amy H Thompson
Janine A Clayton
Chi-Chao Chan
Deborah Tamura
Wadih M Zein
Delphine Blain
Casey Hadsall
John Rowan
Kristen E Bowles
Sikandar G Khan
Takahiro Ueda
Jennifer Boyle
Kyu-Seon Oh
John J DiGiovanna
Kenneth H Kraemer
National Institutes of Health · USCenter for Cancer Research · USNational Cancer Institute · USNational Eye Institute · USMedStar Health · US

Funding

DNA Repair in Human Cancer-Prone Genetic DiseasesZIABC004517 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAEMER, KENNETH H · 2009 to 2024
$26.5M
Histopathology CoreZICEY000461 · NEI · NATIONAL EYE INSTITUTE · PI SCHNEEWEIS, DAVID · 2009 to 2022
$7.7M
Molecular And Immunopathology Of Experimental And Clinical Ocular DiseasesZIAEY000222 · NEI · NATIONAL EYE INSTITUTE · PI CHAN, CHI-CHAO · 2009 to 2015
$7.2M
Intramural NIH HHS Z99 EY999999
6 · The paper itself

Abstract

objectiveTrichothiodystrophy (TTD) is a rare, autosomal recessive disorder characterized by sulfur-deficient brittle hair and multisystem abnormalities. Many TTD patients have a defect in known DNA repair genes. This report systematically evaluates the ocular manifestations of the largest-to-date cohort of TTD patients and xeroderma pigmentosum (XP)/TTD patients.

designCase series.

participantsThirty-two participants, ages 1 to 30 years, referred to the National Eye Institute for examination from 2001 to 2010; 25 had TTD and 7 had XP/TTD.

methodsComplete, age- and developmental stage-appropriate ophthalmic examination.

main outcome measuresVisual acuity (VA), best-corrected VA, ocular motility, state of the ocular surface and corneal endothelial cell density, corneal diameter, and lens assessment.

resultsDevelopmental abnormalities included microcornea (44% TTD), microphthalmia (8% TTD, 14% XP/TTD), nystagmus (40% TTD), and infantile cataracts (56% TTD, 86% XP/TTD). Corrective lenses were required by 65% of the participants, and decreased best-corrected VA was present in 28% of TTD patients and 71% of XP/TTD patients. Degenerative changes included dry eye (32% TTD, 57% XP/TTD) and ocular surface disease identified by ocular surface staining with fluorescein (32% TTD) that usually are exhibited by much older patients in the general population. The 2 oldest TTD patients exhibited clinical signs of retinal/macular degeneration. Four XP/TTD patients presented with corneal neovascularization.

conclusionsThese TTD and XP/TTD study participants had a wide variety of ocular findings including refractive error, infantile cataracts, microcornea, nystagmus, and dry eye/ocular surface disease. Although many of these can be ascribed to abnormal development--likely owing to abnormalities in basal transcription of critical genes--patients may also have a degenerative course. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.

Indexed as

Abnormalities, MultipleAdolescentAdultCataractCell CountChildChild, PreschoolCorneaEndothelium, CornealEye AbnormalitiesFemaleHumansInfantMacular DegenerationMaleMicrophthalmos

Identifiers

PMID21959366
PMCPMC3230678
OpenAlexW2119953742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.